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= 17.80) were statistically signiﬁcant. For the least desirable
heath state (NV), TIME*METHOD interaction was also signif-
icant indicating the two factors were not independent of each
other, F(5,65) = 7.51. These results showed individuals rated the
same health state as less desirable (lower rating) for longer time
horizons and the preference elicitation method used made a dif-
ference. Furthermore, not only were health states not “timeless”,
but preference reversal also occurred resulting in fates perceived
as worse than death. CONCLUSIONS: For the majority of
respondents the utility independence assumption with respect to
time for SG and VAS methods did not hold. Similar to Bala et
al. (1999) and Franic et al. (2003) the results of this study indi-
cated preference weights as measured by SG and VAS techniques
were not “timeless”. Regardless of the preference measure used:
both SG and VAS yield higher scores for shorter time horizons.
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THE BREAST CANCER SCREENING RATES OF GEORGIA
MEDICAID RECIPIENTS
Chen H, Kotzan JA, Martin BC
1The University of Georgia, Athens, GA, USA
OBJECTIVES: The primary objective was to evaluate the per-
formance of the Georgia Medicaid program for breast cancer
screening by comparing the GA Medicaid breast cancer-screen-
ing rate to the national benchmarks. The second objective was
to identify patient and provider characteristics associated with
the mammography use. METHODS: The study was a retro-
spective cohort study. The Health plan Employer Data and Infor-
mation Set (HEDIS) criteria were used to measure the breast
cancer screening rate for women aged 52 to 69. The 1999–2000
GA Medicaid administrative claim data, which included the eli-
gibility ﬁles patient link to the outpatient claims, were used. The
measurement year was 2000 and the 1999–2000 outpatient
claims were searched for mammography claims (ICD9 = V76.11
V76.12 CPT = 76090–76092). This rate was compared with the
National Committee for Quality Assurance (NCQA) breast
cancer-screening rates. Univariate and logistic analyses were used
to identify patient (physician visit level) and provider (physician
specialty and geographic location) characteristics associated with
breast cancer-screening rate. RESULTS: A total of 35,775
women aged 52–69 with two years continuous GA Medicaid eli-
gibility were identiﬁed. Nearly half (45.7%) of the subjects in
the cohort were African-American. Overall, 10,391 (29.1%) had
at least one mammography during the study period. This rate is
much lower than the national Medicaid median (55.6%) and the
national commercial median (74.8%) rates. Women aged 65
years or older had a lower breast cancer-screening rate as com-
pared with women under 65 (22.2% compared with 31.5%).
African-American women had mammography much less often
than caucasian women (18.1% compared with 53.4%). The
results of the logistic models predicting mammography use for
caucasian and African-American women will be reported. CON-
CLUSIONS: The GA Medicaid program breast cancer screening
rates were much lower than the national rates, particularly for
black women. Strategies to increase mammography use for indi-
gent women residing in GA should be sought.
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GAPS IN COLORECTAL CANCER OUTCOMES RESEARCH
Ye X1, Schommer JC1, Castellanos JW1, Sanchez LD1,Wagner S2
1University of Minnesota, Minneapolis, MN, USA; 2Pﬁzer Corporation,
New York, NY, USA
OBJECTIVES: The importance of cancer outcomes research has
been well recognized. The purpose of this study was to examine
the current status of, and identify gaps in, colorectal cancer 
outcomes research. METHODS: Colorectal cancer outcomes
research articles published from 1999 to 2003 were retrieved
using a Medline search with keywords of “colorectal neoplasms
or colorectal cancer” and the following Medical Subject Heading
(MeSH): Economics, Cost and Cost Analysis, Survival, Quality
of life, Personal Satisfaction, Satisfaction, Mental Health,
Outcome Assessment (health care), Health Service Accessibility,
Health Service Research, Quality of Health Care, Quality Assur-
ance (health care), Quality Indicators (health care), Practice
Guideline, and Decision Making. The literature was limited to
the English language and human subjects. Articles excluded were
biological or pathological studies, clinical trials or reviews
mainly answering efﬁcacy-related questions, letters, comments
and editorials. The abstracts were reviewed and classiﬁed by
study designs, study endpoints and study impact levels ( 1) adds
to the knowledge base only; 2) affects practice polices; 3) inﬂu-
ences the delivery of care; 4) leads to changes in health outcomes,
as proposed by the Agency for Health care Research and
Quality)). Full-text articles were retrieved as needed for classiﬁ-
cation. RESULTS: A total of 3255 articles were retrieved by the
search, and 525 met the inclusion criteria for the analysis. Most
were retrospective cohort studies (216, 41.1%). The most
common endpoints were survival (371, 70.6%), followed by
quality of life (102, 19.4%), economic cost (81, 15.4%), and sat-
isfaction (17, 3.2%). A total of 481 articles (91.6%) were in level
1, 26 (5%) in level 2, 16 (3%) in level 3, and 2 (0.4%) in level
4. CONCLUSIONS: Most colorectal cancer outcomes studies
published in the last ﬁve years were focused on survival and rep-
resented impact level 1 research. Satisfaction was almost ignored
and hardly investigated. Outcomes research answering more
than survival questions and representing higher impact levels is
warranted.
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MEASURING CHEMOTHERAPY EFFECTIVENESS IN
NATURALISTIC SETTINGS: THE THREE FACES OF RELATIVE
DOSE INTENSITY
Kilgore KM, Zdanis MR
Cetus Group, LLC,Timonium, MD, USA
OBJECTIVES: In research on the effectiveness of chemotherapy,
a key measure of treatment delivery is average relative dose
intensity (ARDI), which summarizes delivered dosage per unit of
time, relative to an accepted standard. In clinical trials, where
dosages and timing are strictly controlled, the calculation and
use of ARDI are well-understood. In actual practice, however,
naturally-occurring events complicate the computation and
interpretation of this statistic: dosage levels can be reduced, treat-
ment cycles can be delayed or eliminated entirely, and the pre-
scribed regimen can differ materially from the published
standard. In recent naturalistic research studies and clinical per-
formance improvement programs, various alternative methods
of calculating ARDI have been presented, and have been given
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a variety of interpretations. The objectives of this paper are to
critically evaluate the alternatives and present a set of statistics
with known psychometric properties and unambiguous inter-
pretation. METHODS: Data from several cancer registries 
and retrospective studies were mined to identify and categorize
the various naturally-occurring scenarios impacting ARDI.
RESULTS: Three statistics were derived from these samples,
which discriminate among three key ARDI aspects, labeled
“planned ARDI”, “delivered ARDI” and “% Optimal Dose”.
They measure, respectively, the physician’s prescribed dose inten-
sity, the actual delivered dose intensity, and the total delivered
dose independent of time, all relative to the associated standard.
Several visualization and analysis techniques are also presented
that employ these measures to determine the relative contribu-
tion of the various fundamental causes of suboptimal dose
administration. These causes include cycle delay, dose reduction,
treatment attenuation and planned deviation. CONCLUSIONS:
The methods presented provide those engaged in naturalistic
research and clinical performance improvement with a validated
set of statistics and a concise, unambiguous terminology to
measure and interpret the complex treatments involved in the
study of chemotherapy effectiveness.
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Lee WC1, Pashos CL2, Brandman J3,Wang Q1, Botteman MF1
1Abt Associates Inc, Bethesda, MD, USA; 2Abt Associates Inc,
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OBJECTIVES: The “difference in difference” method (DD) is
commonly used in health policy-oriented research. However, it
is seldom used to design and analyze cohort outcomes studies.
We applied the DD method to assess an independent association
between androgen deprivation therapy (ADT) and bone compli-
cations among non-metastatic prostate cancer patients receiving
ADT. METHODS: Using medical claims data from a 5%
national random sample of Medicare beneﬁciaries, prostate
cancer patients who initiated ADT in 1992–94 without bone
metastasis at baseline were identiﬁed (the “ADT” group, N =
3887). Prostate cancer patients without ADT matched on a 1 :2
ratio on the basis of age, race and Charlson comorbidity index
constituted the “comparison” group (N = 7774), a group similar
to the ADT group but unaffected by ADT. We analyzed seven
subsequent years of inpatient, outpatient, and physician claims
data to identify rates of bone complications (e.g., fractures,
osteoporosis/osteopenia) conditional on patient survival.
RESULTS: Fracture incidence rates for the initial baseline two
years and 7 years respectively (conditional on survival) were
11.3% and 83.3% for the ADT group versus 10.4% and 56.3%
for the comparison group. As the temporal effect from the com-
parison group may reﬂect change that would have occurred in
the absence of ADT over time due to aging and disease pro-
gression, we subtracted the change (56.3% – 10.4%) for the
comparison group from the corresponding change (83.3% –
11.3%) for the treatment group, in an effort to account for the
unmeasured time effects. Thus, the difference in difference (DD)
estimate, 26-percentage point change (72% – 45.9%), reﬂects
the association of ADT with fracture. CONCLUSION: This esti-
mate will be valid if the time varying factors (e.g., disease pro-
gression) are consistent or equivalent in treatment and
comparison groups. Future research using clinically detailed data
should assess whether such time-varying factors are different
between those undergoing ADT and those not.
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1The MEDSTAT Group, Ann Arbor, MI, USA; 2Michigan State
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OBJECTIVES: Methods from the traditional survival analysis
are not directly applicable to estimate medical costs since
patients accumulate costs with different rate functions over time,
leading to negatively biased estimates. A number of authors have
incorporated inverse probability weightiness (IPW) technique to
correct for this bias. None of these authors, however, compare
their result with the method, which supposedly yields bias esti-
mates, i.e. OLS over uncensored observations. In this paper, we
test the differences between the coefﬁcient estimates of OLS over
uncensored observations and that of proposed model to deter-
mine whether using weight yields statistically different results.
Moreover, we compare the estimation power of the proposed
alternative models. METHODS: A Hausman kind of test is pro-
posed to compare the weighted estimator and unweighted esti-
mators. Predictive Power tests are used to choose between
alternative models. RESULTS: Our data set consists of an incep-
tion cohort of 773 patients with incident cases of prostate, colon,
lung and breast cancer from 24 Michigan community hospitals
and their afﬁliated oncology units between the years 1994–1997.
Hausman test indicated the results are statistically different. Pre-
dictive Power tests yield that Lin [2003] model is better than
Lin[2000], Carrides et al. [2000] and Bang and Tsiatis [2000].
CONCLUSION: Two conclusions are as follows: 1. If the error
terms are homoskedastic and we fail to reject Hausman test use
unweighted simple OLS over complete observations. 2. Other-
wise, weighted estimators yield consistent results and predictive
power tests can be used to choose among them.
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OBJECTIVES: To propose a method to estimate total medical
cost from censored data. METHODS: In this paper, the inverse
probability of weighted (IPW) least squares method is used to
assess the effect of covariates (e.g. patient and clinical charac-
teristics) on medical cost with censored data. We outlined IPW
least squares as applied to censored medical cost data, including
the statistical properties of the estimation, then introduced
Hausman type of test to compare the estimators calculated by
using IPW least squares and OLS over uncensored data and
applied our method to the estimation of cancer costs RESULTS:
Medicare claim ﬁles are examined to apply our method. Each
patient is followed two years after diagnosis of cancer (breast,
colon, prostate or lung). For patients who have less than two
years of cost and still alive at the end of the study were consid-
ered censored. The reference group fro treatment modalities is
surgery plus adjuvant therapies, the reference group for site of
cancer is lung. Variables that reach statistical signiﬁcance (p <
0.05) include physical function, type of cancer (except colon),
surgery and radiation, radiation only, and chemotherapy and
radiation. Ten additional points in patient’s prior physical func-
tion score decreases total medical cost by 0.7 percent. Prostate
cancer patients and breast cancer patients cost 1.36 and 2.46
times lower than lung cancer patients respectively, these esti-
mates are 1.16 times and 2.40 times according to IPW least
square estimation. CONCLUSIONS: Hausman test suggests that
IPW estimates are signiﬁcantly different (p < 0.05) and suggested
